.-Cardiac failure has been widely associated with an increase in glucose utilization. The aim of our study was to identify factors that mechanistically bridge this link between hyperglycemia and heart failure. Here, we screened the Hybrid Mouse Diversity Panel (HMDP) for substrate-specific cardiomyocyte candidates based on heart transcriptional profile and circulating nutrients. Next, we utilized an in vitro model of rat cardiomyocytes to demonstrate that the gene expression changes were in direct response to substrate abundance. After overlaying candidates of interest with a separate HMDP study evaluating isoproterenol-induced heart failure, we chose to focus on the gene Trp53inp2 as a cardiomyocyte glucose utilization-specific factor. Trp53inp2 gene knockdown in rat cardiomyocytes reduced expression and protein abundance of key glycolytic enzymes. This resulted in reduction of both glucose uptake and glycogen content in cardiomyocytes stimulated with isoproterenol. Furthermore, this reduction effectively blunted the capacity of glucose and isoprotereonol to synergistically induce hypertrophic gene expression and cell size expansion. We conclude that Trp53inp2 serves as regulator of cardiomyocyte glycolytic activity and can consequently regulate hypertrophic response in the context of elevated glucose content.
NEW & NOTEWORTHY Here, we apply a novel method for screening transcripts based on a substrate-specific expression pattern to identify Trp53inp2 as an induced cardiomyocyte glucose utilization factor. We further show that reducing expression of the gene could effectively blunt hypertrophic response in the context of elevated glucose content.
glucose; Trp53inp2; metabolic shift; hypertrophy IMPAIRED HEART METABOLISM has been shown as both contributory and causal to cardiac failure (45, 57, 60, 61) . The heart possesses a unique capacity to utilize a diverse array of substrates and shift preferences as a result of availability and/or disease state. Multiple studies have shown a clear association between heart failure (HF) and reduction of fatty acid oxidation machinery (36, 38, 47, 54) . To account for sustained energetic demands, this reduction in lipid oxidation is generally accompanied by increased glucose utilization (3, 53, 63) . Although these phenomena have been described in detail, the specific mechanisms of cardiomyocyte substrate preference and utilization remain unclear.
The relative contribution of this metabolic shift to a HF phenotype has been widely debated over the past few decades. Much of this debate has focused on differing observations as to the extent of glucose uptake (2, 71) and subsequent oxidation (1, 11, 14, 31) in connection with HF. Many of these discrepancies are thought to be due to the complex etiology underlying HF and the various models used to assess it as well as the idiopathic progression of the disease (15, 26, 61, 68) .
Here, we took a systems genetics approach to identify cardiomyocyte genes whose expression was dependent on a glucose-specific profile. We surveyed a panel of 100 inbred strains that we examined previously for global transcript levels either untreated or treated for 3 wk with isoproterenol. Isoproterenol was used to mimic the catecholamine-driven cardiac hypertrophy and pathological remodeling (51, 69) . We first screened untreated mice for substrate-specific cardiomyocyte candidate genes based on heart transcriptional profiles and circulating nutrients. We then validated these by demonstrating responsiveness to substrate abundance. Next, we overlaid these candidates with results from an isoproterenol panel and identified Trp53inp2 as having striking associations to disease traits.
The gene Trp53inp2 has been implicated recently in several other relevant functions and diseases. It was initially cloned in 2007 as a transcriptional activator of thyroid hormone receptor-␣ in skeletal muscle (6) . Subsequent studies showed the gene as a homolog of the Drosophila deep orange gene, which serves as a crucial regulator of autophagic function in flies and mammals (19, 39, 44, 55) . Another intriguing study in 2011 identified the factor as a potential master regulator of obesity, specifically in the context of adipogenesis (43) .
The gene may exert tissue-specific roles in maintaining cellular metabolic machinery. Substantial work over the past decade has elucidated the interconnectivity of cellular metabolism and autophagic function (22, 50, 58) . Trp53inp2 could also be regulating cardiomyocyte autophagic function, which feeds back on general metabolic and hypertrophic machinery, although before this study, the gene function in heart tissue had yet to be explored. Future examination of direct and specific genes of Trp53inp2 would likely yield substantial insight to the mechanism of gene function. Furthermore, mouse models using tissue-specific overexpression or genetic ablation could provide a more comprehensive physiological view of cardiacspecific functional consequences of Trp53inp2.
In the present study, we identify Trp53inp2 through correlation and screening as a link between cardiomyocyte metabolism and hypertrophy. We show that this gene serves as a regulator of both glycolytic and hypertrophic gene expression, which can effectively blunt the ability of glucose and isoproterenol to synergistically promote cardiomyocyte hypertrophic response.
MATERIALS AND METHODS

Animals.
All animal experiments were approved by the University of California Los Angeles (UCLA) Animal Care and Use Committee in accordance with Public Health Service guidelines. Hybrid Mouse Diversity Panel (HMDP) strains were purchased from Jackson Laboratories and then bred in our colony and housed in a 12-h light-dark cycle room at UCLA and fed a standard chow diet (23) . HMDP studies involving osmotic pump administration containing saline or isoprotereonol were also performed in an earlier study (52) . ISO (30 mg·kg body wt Ϫ1 ·day Ϫ1 ; Sigma) was administered for 21 days in 8-to 10-wk-old female mice using ALZET osmotic minipumps, which were surgically implanted intraperitoneally.
Arrays. Heart expression arrays were performed as described previously (23, 52) . Following homogenization of LV tissue samples in QIAzol, RNA was extracted using the Qiagen miRNAeasy extraction kit and verified as having a RINϾ7 by Agilent Bioanalyzer. Two RNA samples were pooled for each strain/experimental condition whenever possible and arrayed on Illumina Mouse Reference 8 version 2.0 chips. Analysis was conducted using the Neqc algorithm included in the limma R package.
Cell culture. Rat neonatal ventricular cardiomyocytes were isolated and cultured as described previously (48) . Cells were cultured in 0.1% gelatin solution using DMEM supplemented with 10% FBS (Atlanta Biologicals), 100 U/ml penicillin, 100 g/ml streptomycin, and 1 mmol/l sodium pyruvate. For experiments assessing hypertrophic protein levels in cardiomyocytes, treatment conditions also contained 5 M Brefeldin A (Thermo, cat. no. B7450).
Culture media preparation. For experiments altering circulating levels of glucose and palmitate, DMEM containing L-glutamine and no glucose-containing antibiotics were used (Thermo, cat. no. 11966025). This media were then supplemented with 0.1% fatty acid-free bovine serum albumin (Sigma, no. A8808) and the indicated amounts of glucose. To prepare media containing palmitic acid, we used a conjugation method from the same BSA. One micromolar palmitic acid (Sigma, cat. no. P0500) was heated in 150 mM NaCl at 70°for 60 m. This solution was then added to 37°of matched volume of BSA (20 M) in 150 mM NaCl. This final solution was maintained stirring at 37°until it was fully dissolved (typically ϳ2-3 h). This stock solution was added to treatment media at the indicated doses. No FBS was used in media assessing response to either glucose or palmitic acid.
siRNA knockdown. Rat siRNA targets were purchased from Integrated DNA Technologies and ARE listed in Table 1 . All experiments using Trp53inp2 gene knockdown were repeated and confirmed with a different siRNA to verify that the observed effects were not due to off-targeting. For transfection, media were changed to DMEM containing 10% FBS and 1 mmol/l sodium pyruvate and transfected using Lipofectamine 2000 according to manufacturer's protocol.
Ligation injury model. Myocardial injury was performed as described previously (66) . Injury was induced by 30-min ligation of the left anterior descending (LAD) coronary artery, followed by reperfusion. Sham injury was performed in the same manner, with a ligature passed under the LAD, but the LAD was not ligated.
RNA extraction and reverse transcription. Cells or tissues were homogenized in Qiazol (Qiagen), and RNA extraction was carried out using the manufacturer's protocol. RNA samples were reverse transcribed using a High-Capacity cDNA reverse transcription kit (Applied Biosystems) with random primers.
Immunoblot procedure and analysis. Cells and tissues were lysed in whole cell extraction buffer containing 62.5 mM Tris·HCl (pH 6.8), 2% (wt/vol) sodium dodecyl sulfate, and 10% glycerol. Samples were then sonicated and diluted 1:5 in water, and protein content was measured using a BCA protein assay kit (Pierce). Total protein concentration was normalized to 3 g/l, and samples were then denatured in 4ϫ LDS loading buffer (Life Technologies) with 10ϫ reducing agent (Life Technologies) at 95°C for 5 min. Samples were then loaded at 10 l/well into 4 -12% Bis-Tris gels (Invitrogen) and separated out at 130 V for 2 h. Protein was then transferred to PVDF membranes (Immobilon) for 1.5 h at 35 V. Following transfer, membranes were washed with TBST and then blocked in 5% skim milk (Gibco) in TBST for 1 h at room temperature. Membranes were then placed in primary antibodies (1:2,000) on a shaker overnight at 4°C. Primary antibodies were used as follows: CPT-1a (Abcam, no. ab128568, 1:1,000), Hk2 (Sigma, no. SAB2108077, 1:2,000), PFK (Millipore, no. MABS151, 1:1,000), NppA (Sigma, no. SAB2700065, 1:1,000), NppB (Thermo, no. PA1-28352, 1:1,000), and Pln (Abcam, no. ab86930, 1:1,000). The following day, membranes were washed 3ϫ in TBST and then placed in secondary antibodies (1:2,000) for 1 h at room temperature. Blots were then washed three times in TBST and placed Amersham ECL detection solution (GE Health Sciences). Blots were imaged using Imager, and bands were quantified using ImageJ Software.
Quantitative PCR. Quantitative PCR was carried out using a Kappa SYBR Fast quantitative (q)PCR kit as recommended by the manufacturer. Samples were ran on a LightCycler 480 II (Roche) and analyzed using Roche LightCycler 1.5.0 Software. All qPCR targets were normalized to B2M expression and quantified using the ⌬C T method. All qPCR primer sequences were designed using Primer-BLAST (70) and listed in Table 1 .
Cell size assessment. Protocol for changes in cell size was adapted from a previous publication (41) . Briefly, cardiomyocytes were treated as indicated and then washed in PBS (3 times), fixed using 4% PFA, and imaged under phase contrast at ϫ20 magnification. ImageJ software was used for cell area quantification, where individual cells were outlined within 200-m grids and area was quantified. Ten cells per grid were chosen at random and averaged to be n ϭ 1. Throughout the area quantification process the viewer remained blinded to the treatment conditions.
Glucose uptake assay. Glucose uptake was performed using 2-NBDG, a fluorescent analog of glucose (Cayman Chemicals, no. 600470) and adapted from previous studies (4, 46) . Briefly, cells were treated as indicated and then placed in glucose-free DMEM (containing antibiotic and FBS) for 60 min. Media containing 2-NBDG (150 g/ml) were then added and incubated for 20 min. Cells were then washed in ice-cold PBS (3 times), and fluorescence was quantified at excitation/emission of 485/535 nm using a fluorescent plate reader.
Final quantification was normalized to protein content using a BCA assay.
Glycogen content measurement. An assay for quantification of cardiomyocyte glycogen content was adapted from a previous study (18, 40) . Briefly, cardiomyocytes were scraped in PBS and pelleted cells lysed (50 mM Tris·HCl, 2% SDS, and 5% glycerol). Glycogen was then precipitated in isopropanol (Ϫ20°C for 30 min) and transferred through a fine Whatman filter. Glycogen was digested with amyloglucosidase (Sigma) at 50°C for 20 min with 0.1 M sodium acetate buffer (pH 6.0), and then glucose levels were quantified using an Amplex Red (Thermo, no. A12217) glucose oxidase assay. Glucose concentration was normalized to total protein content using a BCA assay.
Statistical analysis. Direct comparisons for experiments were performed using two-tailed Student's t-tests. For multiplecomparison testing, a two-way ANOVA with a Tukey post hoc examination was used. Midweight bicorrelation coefficients and corresponding Student's P values were calculated using the R package WGCNA (33, 34) . All statistical analyses were performed using R statistical software. Values were considered significant at P Ͻ 0.05.
All data are presented as means Ϯ SE.
RESULTS
Screening the HMDP for substrate-specific cardiomyocyte candidates. Given the importance of glucose utilization to heart function and pathophysiology, we initially sought to uncover genes whose expression profile appeared to be specific for the substrate. Therefore, we interrogated Ͼ100 different mouse strains on a standard chow diet within the HMDP for candidate heart transcripts that showed a strong positive correlation with serum glucose and simultaneous negative correlation with circulating lipids (Fig. 1) . To accomplish this, we generated lists of the top 50 genes ranked by midweight bicorrelation coefficient, which showed the strongest positive correlation with serum glucose (Table 2 ). We next utilized the same approach to find the 50 genes that showed the strongest negative correlation with circulating free fatty acids (Table 3 ) and triglycerides (Table  4) . By overlaying these three tables, we found nine candidates whose expression showed a glucose-specific trend. 
Validation of genes regulated by glucose and palmitic acid.
To validate glucose-mediated induction and saturated fatty acid inhibition of these candidates, we adopted an in vitro model of neonatal rat cardiomyocytes (48) . Cardiomyocytes were treated with a varied physiological range of glucose in the media, and qPCR was probed for expression of the nine candidate genes (Fig. 2, A-E) . Of these candidates, Cdc42, Tmem50, Fkbp3, Ppp2r4, and Trp53inp2 all showed a consistent trend of being induced by increasing amounts of exogenous glucose. To further validate the method of identification, we next tested whether expression of the same genes could be suppressed by treatment of palmitate. Of these, Cdc42, Tmem50, Fkbp3, and Trp53inp2 were all reduced in the context of palmitic acid treatment, whereas we did not observe Ppp2r4 being suppressed in these conditions (Fig. 2, F-I ). These data show that four out of the nine potential candidates directly elicited changes in mRNA abundance in response to glucose and palmitic acid.
Trp53inp2 inhibition reduces abundance of key glycolytic machinery. After verifying expression changes from these candidates as a result of substrate content, we next wanted to identify and experimentally validate a candidate gene that exerts control over cardiomyocyte glycolytic machinery. We chose to focus on the gene Trp53inp2, given that it showed strong positive correlation with major regulators of glucose metabolism genes (Table 5 ). In light of these correlations, we tested whether reduction of Trp53inp2 expression could directly impact the mRNA levels of key glycolytic enzymes. Rat cardiomyocytes were transfected with either a scrambled control or siRNA targeting Trp53inp2 gene, where we observed añ 50% reduction in Trp53inp2 expression (Fig. 3A) . Trp53inp2 gene reduction also led to a significant decrease in Cdc42 but not other genes identified in our screen, indicating that Trp53inp2 might directly regulate Cdc42 expression (data not shown). In this model of Trp53inp2 reduction, expression of key glycolytic genes hexokinase 2 (Fig. 3B ) and phosphofructokinase (Fig. 3C) were significantly suppressed. This reduction in two key glycolytic enzymes was accompanied by an increase in the fatty acid oxidation enzym3, carnitine palmitoyltransferase 1a (CPT1a; Fig. 3D ). Changes in metabolic enzyme gene expression were also verified at the level of protein abundance (Fig. 3, E-G) . We also observed a significant reduction in mRNA levels of enolase and increased 3-hydroxyacyl-CoA dehydrogenase; however these changes could not be recapitulated at the protein level (data not shown). Collectively, these observations show that reduction in Trp53inp2 effectively suppresses two key glycolytic enzymes while enhancing CPT1a for fatty acid oxidation.
Trp53inp2 gene expression shows significant associations with clinical traits in a model of isoproterenol-induced hypertrophy. We next asked whether the capacity of Trp53inp2 to regulate glycolytic-specific genes could play a role in the well-established link between glucose utilization and heart failure. In a separate cohort, we performed an HMDP study, where Ͼ100 strains were administered isoproterenol-loaded osmotic pumps for 3 wk to model the pathophysiology of heart failure (51, 52, 69) . Here, we observed dramatic and robust responses to isoproterenol, which mirrored hypertrophy, substantial remodeling, and other relevant perturbations commonly observed in human heart failure (8, 21) . Variation in response to the treatment is shown on an individual strain basis, where a broad range in responses was observed in left ventricle mass (Fig. 4A) and fractional shortening (Fig. 4B) . Consistent with the notion that natural genetic variation was driving differences in response to isoproterenol infusion, a dynamic range of expression responses of Trp53inp2 was also observed (Fig. 4C) . Therefore, we investigated expression of the Trp53inp2 in this study and found significant positive associations between the gene abundance and many clinically relevant traits, including the mitral inflow E-to-A velocity ratio, left ventricular mass, and other left ventricular measurements (Fig. 4D) . We also observed significant negative associations between Trp53inp2 and with fractional shortening and right ventricle mass (Fig. 4D) . These correlations suggest Trp53inp2 as important player in hypertrophic response. We also wanted to see whether the regulation of Trp53inp2 expression was consistent across other models of heart failure. Therefore, we measured gene expression in response to left anterior descending carotid artery ligation. It is interesting to note that in this model we observed opposite modes of regulation; Trp53inp2 expression was suppressed in the infarct area relative to uninjured areas (Fig. 4E) . This might be due to the differences in injury models or indicate that Trp53inp2 gene is a direct target of ␤-adrenergic signaling (as opposed to tissue injury), but additional studies will be required to address this. Trp53inp2 knockdown alters glucose utilization in the presence of isoproterenol. We next tested whether isoproterenol treatment could directly alter Trp53inp2 gene expression and whether this response was dependent on glucose content. Therefore, rat cardiomyocytes were treated with control (PBS) or 60 M isoproterenol in varied concentrations of glucose (Fig. 5A) . Not only was isoproterenol sufficient to induce expression of Trp53inp2, but this induction was greatly enhanced upon glucose content in the media being increased. Since expression of Trp53inp2 was regulated by both glucose and isoproterenol, we hypothesized that this gene sits at a bridging node between cardiomyocyte responses and these conditions. Therefore, we measured glucose uptake and glycogen levels in both basal and isoproterenol-stimulated conditions. In both instances, Trp53inp2 knockdown (KD) did not alter basal regulation of glucose. However, when stimulated with isoproterenol, a significant reduction in both glucose uptake (Fig. 5B ) and glycogen deposition (Fig. 5C ) was observed. These data show that Trp53inp2 KD is sufficient to alter glucose regulation in the context of hypertrophic stimulation.
Reduction of Trp53inp2 blunts the ability of glucose and isoproterenol to synergistically induce hypertrophy. We next tested the hypothesis that Trp53inp2 sits at a node integrating both glucose content and cardiomyocyte hypertrophic response. In light of this hypothesis, we tested whether reducing Trp53inp2 expression and suppressing glycolytic machinery could also blunt hypertrophic responses in a glucose-dependent fashion. Here, we used the expression of well-described cardiac genes natriuretic peptide A (NppA), natriuretic peptide B (NppB), and phospholamban (Pln) as a metric for hypertrophic responsiveness. Consistent with the literature (10, 20, 42, 56) , increasing exogenous glucose content slightly but significantly enhanced NppA and NppB and reduced Pln gene expression (data not shown). To test whether Trp53inp2 was mediating these effects, we again utilized siRNA-mediated knockdown in rat cardiomyocytes. The approximate 50% reduction in Fig. 3 . Trp53inp2 reduction suppresses expression of key glycolytic enzymes. Neonatal rat cardiomyocytes were transfected with either scrambled siRNA vector or siRNA targeting Trp52inp2. After 24 h, the cells were harvested and assessed for the mRNA expression of Trp53inp2 (A), hexokinase 2 (HK2; B), phosphofructokinase (PFK; C), and carnitine palmitoyltransferase (CPT1; D); n ϭ 6/group. All samples were normalized to B2M expression and expressed as means Ϯ SE. All gene expression quantifications of metabolic enzymes are accompanied by Western blots and corresponding quantification (E-G) of the same targets normalized to tubulin (n ϭ 5).
a P Ͻ 0.05; ab P Ͻ 0.001 comparisons done between Iso and control groups at matched glucose contents. All samples are expressed as means Ϯ SE. Trp53inp2 expression modestly repressed the ability of isoproterenol to engage its target genes at lower glucose (5 mM) content; however, at elevated glucose levels (25 mM) this blunting became highly significant at the levels of both mRNA (Fig. 6, A-C) and protein (Fig. 6, D-G) . We next wanted to assess the capacity of Trp53inp2 to regulate hypertrophy using a true functional outcome for the disease. Therefore, we repeated the same experiments and measured changes in cell size as a metric for hypertrophic response. Consistent with changes in mRNA and protein, we observed a capacity of Trp53inp2 reduction to hinder cell size expansion specifically at elevated glucose concentrations (Fig. 6, H and I) . These data suggest that Trp53inp2 functions to bridge cardiomyocyte glucose utilization and hypertrophic response.
H735
DISCUSSION
The present studies identified Trp53inp2 based on the glucose utilization-specific pattern of expression. We further validated this trend in rat cardiomyocytes and explored the association and regulation induction by glucose and suppression by palmitic acid in rat cardiomyocytes. It is important to note that we tested only palmitic acid as a representative and highly abundant free fatty acid. This should not be considered when interpreting regulatory trends for other lipids that exert different effects (e.g., short-chain or polyunsaturated fatty acids). In addition, Trp53inp2 gene silencing effectively reduced the mRNA abundance of key glycolytic machinery. Given that enhanced glucose utilization, specifically glycolysis, has been associated with heart failure phenotypes, we next tested the hypothesis that inhibition of Trp53inp2 would blunt the capacity of glucose to enhance expression of hypertrophic genes. We observed that Trp53inp2 could effectively hinder the expression of hypertrophic genes, an effect that was markedly increased by elevated glucose concentrations. From this study, we conclude that the transcription factor Trp53inp2 serves as a regulator of cardiomyocyte glucose utilization and can offer insight into therapeutic targeting of heart metabolism, especially in the context of hyperglycemia. As mentioned above, Trp53inp2 belongs to a family of known transcription factors, therefore exerting these effects through transcriptional activation of tested genes. It should also be noted that specific targets of the factor are unknown, and the conserved function of the protein could be to regulate processes beyond metabolic machinery.
Large population-based studies have suggested an association between elevated blood glucose and heart failure, especially in the context of type 2 diabetes (7, 27, 30, 62, 64) . Although hyperglycemia in itself is not believed to be causal in heart disease, it certainly appears to exacerbate the severity and mortality of heart failure (17, 28, 35) . Given the high prevalence of type 2 diabetes and heart failure as a comorbidity, molecular mechanisms linking these two disease states are lacking.
Although the ratio of glycolytic activity compared with the extent of oxidation remains unclear in heart failure, the reduction in fatty acid uptake and ␤-oxidation has been quite consistent across models and species (12, 24, 38, 59, 67) , extending to human tissue (53, 54) . As a result, many investigative studies and therapeutic targets have focused on reversing cardiac substrate specificity in the context of the failing heart. This approach of enhancing fat oxidation while simultaneously inhibiting glucose utilization has shown promise under various models and studies in reversing long-term effects of cardiomyocyte dysfunction (29, 32, 60) .
The aim of the study was to identify a bridging node between metabolic syndrome, specifically elevated plasma glucose and heart failure. Many questions follow the present study, including how glucose and palmitic acid impact expression of Trp53inp2. Altering exogenous levels of these two factors has been demonstrated to robustly impact cardiomyocyte physiology, especially in initiating apoptosis and subsequent myofiber degeneration (13, 16) ; however, the underlying pathways remain relatively unclear. Several cellular components have been linked to the capacity of elevated glucose to impair signaling in cardiomyocytes (9, 25, 65) . In addition, palmitate has been shown to activate PKC signaling in cardiomyocytes (49); however, this mechanism has yet to be explored in the context of insulin resistance. These known path- Samples were normalized to B2M. B and C: cardiomyocytes containing Trp53inp2 or control (cntrl) siRNA were evaluated for glucose uptake (B) and glycogen content (C) in both basal and Iso treatment (60 M). Values were normalized to protein content; n ϭ 10/group. All samples expressed as means Ϯ SE.
a P Ͻ 0.05; ab P Ͻ 0.001. Veh, vehicle; KD, knockdown; AU, arbitrary units.
ways might offer insights to the regulation of Trp53inp2 expression.
We note that there are limitations with the neonatal cardiomyocyte system. One caveat of this generalized approach lies in the metabolic nature of rat neonatal cardiomyocytes. Although these cells have been used extensively to assess various aspects of heart function, their utilization of glucose and fatty acids is somewhat distinct from mature adult cardiomyocytes (5, 37) . More generally, neonatal cardiomyocytes rely heavily on glycolysis and lactate oxidation for energy, a process that is reduced at the expense of enhanced fatty acid oxidation as the cells mature. These points should be considered when further interpreting cardiomyocyte metabolism as a surrogate for mature heart function. That being said, we feel this model is a reasonable system for screening due to the fact that gene identification, associations with plasma metabolites, and overlapping with clinical traits were all generated in fully formed adult mouse hearts.
